<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) represent a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of clonal hematopoietic stem cell disorders that are preferentially diagnosed in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain>Aberrant expression of the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> receptor CD44 correlates with poor prognosis in various <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the prognostic impact of CD44 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> serum levels of soluble CD44 standard (solCD44s) were measured in 130 MDS patients (median age 68 years) using an enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="3" pm="."><plain>solCD44s levels were significantly elevated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients as compared to those of healthy donors (p&lt;0.001) and were found to correlate with distinct FAB and WHO subtypes </plain></SENT>
<SENT sid="4" pm="."><plain>The highest levels of solCD44s were found in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed into secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate analysis elevated levels of solCD44s (cut-off level&gt;688.5ng/ml) correlated significantly with shorter overall survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (12 versus 39 months; p&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariate analysis solCD44s displayed prognostic significance independent of the International Prognosis Scoring System (IPSS) </plain></SENT>
<SENT sid="7" pm="."><plain>To test for refined prognostication, IPSS risk groups were split into two separate categories based on the solCD44s levels </plain></SENT>
<SENT sid="8" pm="."><plain>Using this approach, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with a shorter survival were identified both in the IPSS low-risk (p=0.037) and in the IPSS intermediate-1-risk group (p=0.015) </plain></SENT>
<SENT sid="9" pm="."><plain>The CD44s-adjusted IPSS defines a cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with unfavorable prognosis, which might be helpful in risk stratification and in therapeutic algorithms </plain></SENT>
</text></document>